Orgenesis Inc.

ORGS

US68619K3032

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 07:53:48 12/05/2026 pm IST			5-day change	1st Jan Change
0.001000 ^USD	-99.67%		-99.83%	-99.33%

26/03	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
26/03	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI

Orgenesis Inc.(NasdaqCM:ORGS) dropped from S&P TMI Index

Published on 10/23/2024

S&P Capital IQ

ORGENESIS INC.

-99.67%

S&P TMI

-0.41%

Orgenesis Inc.(NasdaqCM:ORGS) dropped from S&P TMI Index

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
	ORGENESIS INC.	0.001000USD	-99.67%	-99.83%	29.4L
	S&P TMI	7,357.78PTS	-0.41%	+1.49%	-

Latest news about Orgenesis Inc.

26/03	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
26/03	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI
26/03	Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc..	CI
14/03	Orgenesis Inc. Announces Board Appointments, Effective March 10, 2026	CI
14/03	Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026	CI
26/25/26	Orgenesis Inc. Announces Resignation of Director Ashish Nanda, Effective August 21, 2025	CI
20/25/20	Orgenesis Inc. Announces Resignation of Victor Miller as Chief Financial Officer	CI
20/25/20	Orgenesis Inc. Announces Executive and Board Changes	CI
06/25/06	Orgenesis Inc. completed the acquisition of Certain assets of Neurocords LLC for $5.7 million.	CI
22/25/22	Orgenesis Inc. announced that it expects to receive $5 million in funding	CI
28/24/28	Orgenesis Inc. Announces Resignation of Jagannathan Bhalaji as A Director	CI
13/24/13	Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	CI
13/24/13	Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
02/24/02	Orgenesis Inc. Announces Board Appointments	CI
24/24/24	Orgenesis Inc. Announces Resignation of Mark Goodman as Director	CI

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâ€™s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâ€™s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company